Clinical Trials
The clinical trials conducted by the Dunlevie MFM Center will test therapies and treatment algorithms for major obstetrical conditions including preeclampsia, placenta accreta and fetal growth restriction. Prospective clinical research studies and clinical trials conducted will bring new knowledge and improved care for conditions otherwise causing severe maternal and neonatal morbidity and mortality. We are actively engaged in several national collaborative trials, including studies sponsored by the National Heart Lung and Blood Institute (NHLBI) and National Institute of Child Health and Human Development (NICHD).
These trials will prove the efficacy of interventions that ensure safer pregnancies for mothers with underlying conditions such as heart disease, cancer, epilepsy, and diabetes; and of treatments for pressing obstetrical issues like preterm labor, placenta accreta, hemorrhage, and cesarean section prevention. By leading these studies at the Center, we can move from research to proven solutions and health impact faster.
EPOCH Study at Stanford
The EPOCH Study at Stanford is designed to study the long term effects of preeclampsia on women's cardiovascular health. Principal Investigators Mark Hlatky and Virginia D. Winn hope the study findings will help lower the risk of heart disease for women.
Chronic Hypertension and Pregnancy (CHAP)
The purpose CHAP is to evaluate whether a blood pressure treatment strategy during pregnancy to achieve targets that are recommended for non-pregnant adults (<140/90 mmHg) is effective and safe.
Antenatal Late Prenatal Steroids (ALPS)
Between 2010 and 2015, the Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo- Controlled Trial was conducted in the U.S. to determine if giving steroids to mothers who are at risk for late preterm delivery will decrease the likelihood that babies will need respiratory (breathing) support like a ventilator or oxygen soon after birth.
MATISSE Maternal Vaccine Study
The MATISSE maternal vaccine study is working to understand if a potential vaccine for respiratory syncytial virus (RSV) could activate a mother’s immune system to create antibodies, or protective defenses, against RSV that could be passed on to their developing baby. The MATISSE study will help us understand if this maternal vaccine is safe and could help protect babies from RSV after they are born.
Unlocking Answers About Pregnancy Loss Through Multiomics
The HOPE project works to Harness multiple Opportunities for Pregnancy loss Exploration. This research will provide answers to both these questions using a multi-pronged approach involving molecular profiling, machine learning, and whole genome sequencing of the trio at the center of recurrent pregnancy loss — the mother, the father, and past pregnancies.
Stanford Ob/Gyn Currently Enrolling Studies
Stanford’s Division of Maternal-Fetal Medicine and Obstetrics has an outstanding record of scientific investigation. From early pregnancy and placentation studies to prenatal diagnosis and fetal therapy research, to clinical trials and cohort studies covering a broad spectrum of maternal-fetal and obstetrical complications.
"What will make us great is truly understanding what can go wrong for a mother or baby, and using that scientific understanding to transform treatment. Women and babies suffer and die because we haven’t invested enough. We know science can transform outcomes, and Stanford is poised to be a world leader in this field.